论文部分内容阅读
面对两个重磅炸弹产品抗抑郁药再普乐和抗肿瘤药健择的专利到期,一贯风格稳健的老牌跨国药企礼来也坐不住了。3月,礼来全球董事长、总裁兼首席执行官李励达(JohnLechleiter)在北京接受采访时提出了其开源节流的应对策略:大幅节省运营成本10亿美元;寻找新的逆周期增长引擎。值得关注的是,在新的增长点中,除了所有跨国药企都关注的增加新兴市场投入,李励达还特别提到了近期不会受到专利到期影响的ED(勃起功能障碍)产品希爱力。礼来应该选对了押宝对象。2011年,希爱力在全球的销售
In the face of two blockbuster anti-depressant drugs Zaplyr and anti-cancer drugs Jian-choice patent expires, has always been a stable style of the old multinational pharmaceutical company Eli Lilly also sit still. In March, Eli Lilly’s Global Chairman, President and Chief Executive Officer John Leechiter presented an open-budget tactic in an interview in Beijing: Significant savings in operating costs of $ 1 billion; looking for a new counter-cyclical growth engine. What deserves our attention is that Li added a special note to EDI (erectile dysfunction) products, which will not be affected by the patent expiration date, in addition to the increased investment in emerging markets that all multinational pharmaceutical companies are concerned about in the new growth point. Eli Lilly should have chosen the right betting object. 2011, Greek love in the global sales